RE:RE:RE:RE:What have we got here? March 31, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB).
https://www.oncolyticsbiotech.com/press-releases/detail/565/oncolytics-biotech-provides-positive-safety-update-on-the